FHC, INC.

Medtech · Private

MR-compatible stereotactic delivery device for widespread brain distribution of nucleic acid therapeutics

Grants
$1.2M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
2 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Instruments for Micro-Magnetic Stimulation of the Brain in Animals$317,160
Federal grantDepartment of Health and Human Services · Phase I · Instruments for Micro-Magnetic Stimulation of the Brain in Animals$350,000
Federal grantDepartment of Health and Human Services · Phase I · Optimizing Direct Delivery of Nucleic Acid Therapeutics$402,820
Federal grantDepartment of Health and Human Services · Phase I · Optimizing Direct Delivery of Nucleic Acid Therapeutics$99,439
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1716ALELOPHARMA INC.——
1717Procyrion, Inc.—$109M
1718EZ LAB LIMITED LIABILITY COMPANY——
1719FHC, INC.——
1720VOLTMED, INC.——
1721QUANTUMMED INC——
1722MEDICASAFE, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 2 granted of 3

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.